(GXI) Gerresheimer - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: XETRA (Germany) | Market Cap: 944m EUR | Total Return: -53.8% in 12m
Avg Turnover: 5.61M
EPS Trend: -66.4%
Qual. Beats: 0
Rev. Trend: 93.8%
Qual. Beats: -1
Warnings
High Debt/EBITDA (5.6) with thin interest coverage (1.3)
High Debt while negative Cash Flow
Altman Z'' 0.92 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Gerresheimer AG is a Germany-based manufacturer specializing in specialty packaging and drug delivery systems for the pharmaceutical, biotech, and healthcare sectors. The company operates through three core divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies, providing a portfolio that includes prefillable syringes, inhalers, and insulin pens.
The business model relies on high switching costs and rigorous regulatory integration, as primary packaging must meet strict biocompatibility and safety standards to gain market approval. As drug delivery shifts toward self-administration, Gerresheimer has expanded into complex mechanical and electronic devices like auto-injectors.
The firm maintains a global production footprint to serve pharmacy chains, wholesalers, and clinical laboratories. For a deeper look at the companys valuation metrics, consider exploring the data on ValueRay. Founded in 1864, the company has transitioned from a traditional glassmaker to a high-tech partner for the global life sciences industry.
- High demand for GLP-1 drug delivery systems drives plastic and devices revenue
- Expansion of prefillable syringe capacity scales long term high margin growth
- Volatile energy and raw material costs impact glass manufacturing profitability
- Strategic shift toward biotech and specialized drug delivery improves operating margins
- High capital expenditure requirements for capacity expansion pressure short term free cash flow
| Net Income: 23.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 1.54 > 1.0 |
| NWC/Revenue: -0.83% < 20% (prev -10.56%; Δ 9.72% < -1%) |
| CFO/TA 0.05 > 3% & CFO 253.6m > Net Income 23.4m |
| Net Debt (2.23b) to EBITDA (394.9m): 5.65 < 3 |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.5m) vs 12m ago 0.0% < -2% |
| Gross Margin: 26.89% > 18% (prev 0.29%; Δ 2.66k% > 0.5%) |
| Asset Turnover: 54.55% > 50% (prev 56.47%; Δ -1.92% > 0%) |
| Interest Coverage Ratio: 1.33 > 6 (EBITDA TTM 394.9m / Interest Expense TTM 106.9m) |
| A: -0.00 (Total Current Assets 1.09b - Total Current Liabilities 1.11b) / Total Assets 4.69b |
| B: 0.16 (Retained Earnings 734.2m / Total Assets 4.69b) |
| C: 0.03 (EBIT TTM 142.0m / Avg Total Assets 4.13b) |
| D: 0.19 (Book Value of Equity 623.4m / Total Liabilities 3.26b) |
| Altman-Z'' = 0.92 = BB |
| DSRI: 0.92 (Receivables 291.1m/281.9m, Revenue 2.25b/2.01b) |
| GMI: 1.08 (GM 26.89% / 29.09%) |
| AQI: 1.05 (AQ_t 0.38 / AQ_t-1 0.36) |
| SGI: 1.12 (Revenue 2.25b / 2.01b) |
| TATA: -0.05 (NI 23.4m - CFO 253.6m) / TA 4.69b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at EUR 27.38 with a total of 114,887 shares traded.
Over the past week, the price has changed by +10.31%,
over one month by +14.18%,
over three months by +74.39% and
over the past year by -53.83%.
Gerresheimer has no consensus analysts rating.
P/E Trailing = 40.1765
P/E Forward = 9.3458
P/S = 0.4193
P/B = 0.6608
P/EG = 1.2325
Revenue TTM = 2.25b EUR
EBIT TTM = 142.0m EUR
EBITDA TTM = 394.9m EUR
Long Term Debt = 1.71b EUR (from longTermDebt, last quarter)
Short Term Debt = 604.9m EUR (from shortTermDebt, last quarter)
Debt = 2.38b EUR (from shortLongTermDebtTotal, last quarter) + Leases 65.5m
Net Debt = 2.23b EUR (calculated: Debt 2.38b - CCE 145.9m)
Enterprise Value = 3.17b EUR (943.6m + Debt 2.38b - CCE 145.9m)
Interest Coverage Ratio = 1.33 (Ebit TTM 142.0m / Interest Expense TTM 106.9m)
EV/FCF = -36.60x (Enterprise Value 3.17b / FCF TTM -86.7m)
FCF Yield = -2.73% (FCF TTM -86.7m / Enterprise Value 3.17b)
FCF Margin = -3.85% (FCF TTM -86.7m / Revenue TTM 2.25b)
Net Margin = 1.04% (Net Income TTM 23.4m / Revenue TTM 2.25b)
Gross Margin = 26.89% ((Revenue TTM 2.25b - Cost of Revenue TTM 1.65b) / Revenue TTM)
Gross Margin QoQ = 24.77% (prev 26.28%)
Tobins Q-Ratio = 0.68 (Enterprise Value 3.17b / Total Assets 4.69b)
Interest Expense / Debt = 4.50% (Interest Expense 106.9m / Debt 2.38b)
Taxrate = 23.50% (34.5m / 146.8m)
NOPAT = 108.6m (EBIT 142.0m * (1 - 23.50%))
Current Ratio = 0.98 (Total Current Assets 1.09b / Total Current Liabilities 1.11b)
Debt / Equity = 1.69 (Debt 2.38b / totalStockholderEquity, last quarter 1.40b)
Debt / EBITDA = 5.65 (Net Debt 2.23b / EBITDA 394.9m)
Debt / FCF = -25.72 (negative FCF - burning cash) (Net Debt 2.23b / FCF TTM -86.7m)
Total Stockholder Equity = 1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.57% (Net Income 23.4m / Total Assets 4.69b)
RoE = 1.59% (Net Income TTM 23.4m / Total Stockholder Equity 1.47b)
RoCE = 4.48% (EBIT 142.0m / Capital Employed (Equity 1.47b + L.T.Debt 1.71b))
RoIC = 2.60% (NOPAT 108.6m / Invested Capital 4.18b)
WACC = 4.83% (E(943.6m)/V(3.32b) * Re(8.33%) + D(2.38b)/V(3.32b) * Rd(4.50%) * (1-Tc(0.23)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 44.72 | Cagr: 2.28%
[DCF] Fair Price = unknown (Cash Flow -86.7m)
EPS Correlation: -66.43 | EPS CAGR: -22.84% | SUE: 0.33 | # QB: 0
Revenue Correlation: 93.79 | Revenue CAGR: 6.12% | SUE: -0.96 | # QB: -1